Radiopharm Theranostics Ltd RADX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Radiopharm Theranostics Ltd (RADX) is a healthcare company listed in the US with a market value of about $11M. In fiscal year 2026 it had revenue of $2M and net income of -$38M, a net margin of -2057.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -89%.
About Radiopharm Theranostics
Radiopharm Theranostics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $292359 in 2023 to $2M in 2026, growth of about 85.6% a year. It was profitable in 0 of the last 4 years in our data. Its share count fell by 29% over three years (buybacks).
Score: 1.2 / 5
Checks passed
- Profit margin improving
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $2M | $4M | $299228 | $292359 |
| Net income | -$38M | -$38M | -$48M | -$35M |
| Free cash flow | -$36M | — | — | -$23M |
| EPS (diluted) | $-3.76 | $-2.65 | $-3.32 | $-2.39 |
| Net margin | -2057.5% | -1055.3% | -16024.3% | -11838.6% |
| ROIC | — | -70.3% | -136.3% | -59.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Radiopharm Theranostics pay a dividend?
Not currently.
Is Radiopharm Theranostics a good stock to buy?
We do not give buy or sell advice. Radiopharm Theranostics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.